{"id":"W2916100539","doi":"10.1016/s1470-2045(18)30907-0","title":"Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":175,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; University of Calgary","funders":"Janssen Pharmaceuticals; National Cancer Institute; Takeda Pharmaceuticals U.S.A.; Sanofi Genzyme; Genentech; National Institutes of Health; European Society for Medical Oncology; Eisai; Bayer Fund; Clovis Oncology; Active Biotech; Ipsen Biopharmaceuticals; Bavarian Nordic; Novartis; AbbVie; Exelixis; Sanofi; Merck; GlaxoSmithKline; Roche; Astellas Pharma US; Pfizer; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim","keywords":"Cabozantinib; Medicine; Renal cell carcinoma; Retrospective cohort study; Oncology; Cohort; Internal medicine; Urology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007883678,0.0003076003,0.00124683,0.0001262706,0.00006484344,0.00001275208,0.0003020532,0.0001546063,0.0003551491],"category_scores_gemma":[0.00004574644,0.0002092873,0.0001200202,0.0003469936,0.00008802306,0.00006033683,0.0001633648,0.0007093539,0.0007041008],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00082841,"about_ca_system_score_gemma":0.0002359521,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006059395,"about_ca_topic_score_gemma":0.0004119916,"domain_scores_codex":[0.9974395,0.0003489246,0.0004506489,0.0006625755,0.0003934084,0.0007049622],"domain_scores_gemma":[0.9982461,0.0002373448,0.0002242335,0.001044232,0.0001167694,0.0001312936],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002877929,0.001990076,0.9735431,0.00006762097,0.0000516556,0.0007232099,0.00153768,0.00004809671,0.01816124,0.00001160074,0.0007478812,0.0002399245],"study_design_scores_gemma":[0.02350082,0.005111143,0.961503,0.00002238829,0.0001942402,0.00004671185,0.001290865,0.0002922117,0.00571162,0.00001113235,0.002120823,0.0001950834],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8984776,0.0002525576,0.000003187954,0.0005257804,0.0003505091,0.003717454,0.000007595168,0.00004901008,0.09661629],"genre_scores_gemma":[0.9917942,0.00005870477,0.0004686915,0.0004420952,0.0002697152,0.0001857945,0.00001888488,0.00004926495,0.006712692],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09331654,"threshold_uncertainty_score":0.9050025,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01779356237453034,"score_gpt":0.2916839099226428,"score_spread":0.2738903475481125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}